CSL commenced plasma fractionation for Australia in 1952. Today, CSL Biotherapies continues to be the chosen national plasma fractionator of Australia and is also the chosen national plasma fractionator of New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. Regulated by the Therapeutic Goods Administration, a regulator held in high regard worldwide, working together with CSL Biotherapies, health authorities and blood services in these countries deliver the benefits that self-sufficiency in plasma-derived therapies provides.
These benefits include:
- peace-of-mind regarding the quality, safety, cost and assured supply of plasma-derived therapies fractionated from plasma collected within their own countries, and
- a sustainable, reliable and high quality source of plasma-derived therapies, developed to treat serious medical conditions including immunodeficiencies, a range of haematological and neurological disorders, haemophilia, haemolytic disease of the newborn and trauma. A range of products is also available to provide protection against infectious diseases including hepatitis B, tetanus, chickenpox and cytomegalovirus.
We focus on continued excellence in service delivery to ensure our customers are provided with tailored product support, supply chain management and customer service.